The function of the p53 tumor suppressor protein is regulated by interaction with Mdm2, which targets p53 for ubiquitin dependent degradation. We show here that like p53, p73a forms an interaction with Mdm2, both in vitro and in cells, but this does not result in the degradation of the p73a protein. The human papillomavirus E6 protein also fails to degrade p73a, suggesting that the mechanisms governing p73a stability are distinct from those known to regulate p53 stability. However, the interaction of Mdm2 with 73a is sucient to impede p73a transcriptional function, despite the lack of degradation.
Introduction
The p53 protein plays an important role in preventing tumor development and most cancers show evidence for loss of p53 function (Hollstein et al., 1994) . p53 is activated in response to cellular stress such as DNA damage or oncogene activation, and functions to inhibit cell growth by causing cell cycle arrest or apoptosis (Levine, 1997) . In this way p53 is thought to prevent the continued division of cells which are damaged or have undergone potentially oncogenic changes. Several p53 related proteins have recently been identi®ed and one of these, named p73, was shown to share at least some functions with p53, including the ability to function as a transcription factor and cause apoptosis following transient overexpression (Jost et al., 1997; Kaghad et al., 1997) . Four isoforms of p73 resulting from dierential splicing of the p73 message have been described (Jost et al., 1997; Kaghad et al., 1997; De Laurenzi et al., 1998) ; p73a, the full-length protein, and three shorter variants expressed from spliced messages. Although each of these proteins share functional similarities with p53, dierences in eciency of transcriptional activation of various p53 target genes, and dierences in expression have been noted (De Laurenzi et al., 1998; Zhu et al., 1998) . Given the similarity to p53, it is possible that p73 also functions as a tumor suppressor protein, and there is evidence that the chromosomal region containing p73 is deleted in some neuroblastomas.
The function of p53 is controlled to a large extent by regulation of protein stability, and in normally cycling cells the p53 protein is targeted for degradation through the proteasome by interaction with Mdm2 (BoÈ ttger et al., 1997; Haupt et al., 1997; Kubbutat et al., 1997) . Mdm2 is the product of a p53 inducible gene, leading to a negative feedback loop in undamaged cells in which p53 transcriptionally activates expression of Mdm2, which then targets the p53 protein for degradation . Mdm2 therefore eciently inhibits p53 transcriptional activity, both by targeting p53 for degradation and directly, by interacting with and obscuring the N-terminal trans-activation domain of p53 (Momand et al., 1992; Oliner et al., 1993) . Following activation of a p53 response, p53 becomes resistant to Mdm2 mediated degradation and protein levels are rapidly elevated in the cell. This results in the transcriptional activation of p53 responsive genes, such as p21 Waf1/Cip1 and Bax, which contribute to the cell cycle arrest and apoptotic responses. p53 degradation is also enhanced following interaction with the E6 protein encoded by some human papillomaviruses (HPVs) (Schener et al., 1990) , and the expression of E6 prevents activation of p53 following DNA damage (Foster et al., 1994) . Cervical carcinomas, which arise following infection with these HPV types, rarely show evidence for p53 mutation, but have lost normal p53 activity through expression of E6 (Crook et al., 1992) . Although both Mdm2 and E6 target p53 for degradation through ubiquitin dependent proteolysis, the binding requirements of E6 for p53 are entirely dierent from Mdm2, and degradation by E6 is independent of Mdm2 . Despite the similarity in function between p53 and p73, p73 is not activated by DNA damage (Kaghad et al., 1997) and the mechanisms regulating p73 function are not clear. We therefore sought to determine whether p73 stability is also regulated by degradation through the proteasome, and whether known regulators of p53 degradation, such as Mdm2, aect p73 stability.
Results

Detection of endogenous p73a after proteasome inhibition
We generated an antibody against a C-terminal peptide of p73a, and used this to examine the eects of inhibition of the proteasome on endogenous p73a protein levels in U2OS cells, which contain wild type p53, and Saos-2 cells, which do not express p53. Western blot analysis of protein expression in U2OS cells showed that both p73a and p53 levels increase following treatment with LLnL ( Figure 1a ). As LLnL can also inhibit calpain at higher concentrations, we con®rmed the role of the proteasome in regulating p73a levels using lactacystine, a speci®c proteasome inhibitor (Figure 1b) . Treatment of Saos-2 cells with the proteasome inhibitors revealed expression of p73a, which had previously not been detected in these cells (Kaghad et al., 1997) (Figure 1 ). Similar results were also seen in wild type p53 expressing MCF-7 cells (data not shown). Interestingly, the p73a protein which accumulated following proteasome inhibition migrated more quickly than endogenous p73a, suggesting the existence of another p73 isoform or dierences in posttranslational modi®cation.
Association of p73a and Mdm2 in vitro
The principal regulator of p53 stability in cells is the Mdm2 protein, and interaction between p53 and Mdm2 results in the degradation of p53 through the proteasome. The Mdm2 binding region on p53 has been extremely well de®ned and p73 shares this domain (Picksley et al., 1994; Kussie et al., 1996) . We therefore examined the potential for interaction between p73a and Mdm2 by co-precipitation from mixtures of in vitro translated proteins (Figure 2 ). In order to compare the amount of each protein being coprecipitated we constructed Flag-tagged versions of p53 and p73 (FLp53 and FLp73), thereby allowing detection of both proteins with the same antibody. This assay clearly showed that both p53 and p73a form a complex with Mdm2 and that both proteins could be co-precipitated through either Mdm2 (Figure 2a ) or FLp53/p73a (Figure 2b ). Deletion of the p53 binding site in the Mdm2 mutant Mdm2D58 ± 89 prevented interaction with both p53 and p73a, indicating that both proteins bind to a similar region on Mdm2.
Association of p73a and Mdm2 in cells
To con®rm that the interaction between p73a and Mdm2 can also occur in cells, we carried out coprecipitation from transiently transfected U2OS cells ( Figure 3a ). As seen in the in vitro association assays, wild type Mdm2 but not Mdm2D58 ± 89, formed a complex with both p53 and p73a. As shown previously, co-transfection of wild type Mdm2 with p53 resulted in a reduction in p53 protein levels, due to targeted degradation by Mdm2. A similar reduction in p73a levels was not seen in these experiments, suggesting that the stability of p73a may not be regulated by Mdm2 in the same way as p53. Since p73a appeared to bind to the p53 binding region of Mdm2, we also tested another deletion mutant of Mdm2 (D222 ± 437), which retains the ability to interact with p53 but cannot target p53 for degradation (Kubbutat et al., 1997) . Both p53 and p73a were clearly co-precipitated with the Mdm2 D222 ± 437 protein following co-transfection in Saos-2 cells, although no detectable association was seen with the Mdm2 mutant D58 ± 89, which lacks the p53 binding domain (Figure 3b ). It should be noted, however, that Mdm2 D222 ± 437 is expressed at signi®cantly higher levels than Mdm2 D58 ± 89 in these cells (Kubbutat et al., 1999) . Interestingly, Western blot analysis of total p53 or p73a protein levels in these transfected cells con®rmed our previous observation that the Mdm2D222 ± 437 protein can increase p53 expression, presumably by dominant negative inhibition of degradation by the endogenous Mdm2 protein (Kubbutat et al., 1997) . By contrast, no such elevation of p73a was seen following co-expression with Mdm2D222 ± 437, again suggesting that a similar regulation of p73a stability by endogenous Mdm2 was not taking place. We therefore looked directly at the eect of Mdm2 expression of p53 and p73a stability. Co-expression of Mdm2 with p53 results in the reduction of p53 protein levels due to enhanced degradation, using either mouse or human p53 in U2OS or Saos-2 cells (Figure 4) . However, no reduction in p73a protein levels could be seen following mouse or human Mdm2 expression, and when Mdm2, p53 and p73a were co-expressed in the same cells, reduction of p53 was seen in the absence of any detectable change in p73a levels. Interestingly, in Saos-2 cells p53 levels were slightly but consistently higher in cells contransfected with Mdm2 and p73a, compared to cells transfected with p53 and Mdm2 alone, suggesting that the interaction of p73a with Mdm2 may be protecting p53 from degradation.
Resistance of p73a to E6 mediated degradation
In addition to Mdm2, the human papillomavirus type 16 E6 protein can also target p53 for ubiquitin dependent degradation through the proteasome. Degradation of p53 by E6 can be detected following Accumulation of p73a was monitored by Western blot analysis using anti-p73a rabbit polyclonal antibody and p53 was detected with DO-1. (b) U2OS and Saos-2 cells were untreated, treated with 50 mM LLnL or 50 mM lactacystin for 13 h as indicated. Accumulation of p73a and p53 was detected as in (a) incubation of in vitro translated proteins in reticulocyte lysates. This degradation is ATP dependent and can be inhibited by the addition of ATPgS (Figure 5a ), when slowly migrating ubiquitinated forms of p53 can be detected. Under similar assay conditions, neither ubiquitinated p73a nor loss of p73a was detected (Figure 5b ), suggesting that like Mdm2, E6 is unable to target p73a for degradation.
Inhibition of p73a transcriptional function by Mdm2
Mdm2 can regulate p53 function both by targeting p53 for degradation and by directly concealing the transactivation domain of p53. We were therefore interested to determine whether Mdm2 could also regulate p73a activity in the absence of degradation. Figure 6 shows the eects of co-expression of Mdm2 on the transcriptional activity of p53 and p73a as measured using the p53 responsive bax promoter (Miyashita and Reed, 1995) . As shown previously for other p53 responsive promoters (Jost et al., 1997; Kaghad et al., 1997) , the isolated bax promoter was also eciently activated by p73a, although the endogenous bax gene is not clearly transcriptionally activated following p73a expression (Zhu et al., 1998) . These analyses showed that although Mdm2 cannot eciently target p73a for degradation, co-expression of either mouse Mdm2 (Figure 6 ) or human Mdm2 (data not shown) inhibits the transcriptional activity of p73a, although this appears to be somewhat less ecient than the inhibition of p53 function. Expression of an Mdm2 mutant which is unable to interact with p53 or p73a (Mdm2DXM for the mouse protein) did not inhibit the transcriptional activity of either p53 or p73a.
Discussion
We show here that the p53 related protein p73a is competent for binding to Mdm2, but that this interaction does not lead to the degradation of p73a. Although it is possible that the lack of degradation re¯ects, in part, less ecient binding of p73a to Mdm2, the inhibition of p73a transcriptional function by Mdm2 indicates that the interaction can have functional consequences. These data are consistent with the fact that p73 levels do not accumulate following DNA damage, where Mdm2-mediated degradation of p53 is impaired, and the observation that the lethality of Mdm2 de®cient mice can be rescued by deletion of p53 alone (reviewed in Kubbutat et al., 1997) . We have recently shown that p53 mutants lacking the extreme C-terminus become resistant to Mdm2 mediated degradation, despite retaining the ability to bind Mdm2 . Although the C-terminal sequences of p53 are moderately well conserved in p73a, it is possible that the additional 243 amino acids found in p73a inhibit the normal contribution of this region to degradation. The observation that inhibition of the proteasome increases endogenous p73a levels suggests that p73a stability may be regulated by another protein which functions in a manner similar to Mdm2. One candidate ag-tagged p73a (FL p73a) and wild type Mdm2 or Mdm2D58 ± 89 as indicated above. Protein complexes were immunoprecipitated with Ab-1, an anti-Mdm2 antibody (left panel) and co-precipitating p53 or p73a detected by Western blotting with M5, an anti-¯ag antibody. As controls, 5% of the total lysate was Western blotted with M5 to detect FLp53 and FLp73a (central panel) or with Ab-1 to detect Mdm2 (right panel). (b) Saos-2 cells were co-transfected with plasmids expressing¯ag-tagged human p53 (FLp53) or ag-tagged p73a (FLp73a) and Mdm2D58 ± 89 or Mdm2D222 ± 437. Protein complexes were immunoprecipitated with SMP14, an anti-Mdm2 antibody (left panel) and co-precipitating FLp53 or FLp73a was detected by Western blotting with M5, an anti-¯ag antibody. As a control, the amount of Flp53 and FLp73a protein in the 5% of the total lysate was determined by Western blotting with M5 (right panel)
for such a protein might be the Mdm2 related protein, MdmX (Shvarts et al., 1996) , which would also be expected to interact with p73a through the Mdm2 binding domain at the N-terminus. A role for MdmX in regulating protein stability has yet to be determined, however, and it is also possible that inhibition of the proteasome in these experiments stabilizes a protein that regulates p73a expression, rather than p73a itself. The HPV E6 protein, which eciently targets p53 for Figure 4 Mdm2 down-regulates p53 but not p73a levels. U20S (a and b) or Saos-2 (c) cells were co-transfected with 3 mg p53, HAtagged p73a, or both p53 and HAp73a, along with 9 mg of empty vector or murine Mdm2 expression plasmid (a and c) or human Mdm2 expression plasmid (b). Proteins were analysed by Western blotting using rabbit polyclonal anti-p73a antibody and DO-1 antibody to detect HA-p73a and p53, respectively. Plasmid expressing the green¯uorescent protein (GFP) was also cotransfected, and equal transfection eciency was con®rmed by reprobing the blots with anti-GFP antibody Figure 6 Mdm2 inhibits the transcriptional activation function of p73a. Saos-2 cells were co-transfected with Bax-luc reporter (5 mg) and empty vector (pCB6+) or plasmids expressing p53 or HA-p73a (0.1 mg) and murine wild type Mdm2 or the non-p53 binding mutant Mdm2DXM (0.3 mg) as indicated. Plasmid expressing the b-galactosidase was also co-transfected to monitor transfection eciency. Fold activation is expressed relative to the empty vector degradation, also had no eect on the stability of p73a in in vitro assays. This is consistent with a recent publication showing that p73b is not sensitive to E6 mediated degradation in cells (Prabhu et al., 1998) , and re¯ects the inability of E6 to bind p73 (Marin et al., 1998) . Other viral oncoproteins which interact with p53, such as simian virus 40 T and adenovirus E1B 55K, are also unable to form a complex with p73 (Marin et al., 1998; Roth et al., 1998) .
Previous studies have shown that the interaction between Mdm2 and p53 is sucient to inhibit the transcriptional activity of p53, by interfering with the function of the N-terminal trans-activation domain which contacts other components of the transcriptional machinery like p300 and the TAFs (Oliner et al., 1993; Kussie et al., 1996) . The interaction between p73a and Mdm2 would therefore also be predicted to inhibit p73a transcriptional function, and we show inhibition of the ability of p73a to activate transcription from the bax promoters following co-expression of Mdm2. Inhibition of p73a function by Mdm2 appeared to be less ecient than inhibition of p53 function, possibly re¯ecting the inability of Mdm2 to degrade p73a. Nevertheless, p73a function is likely to be regulated to some extent by interaction with Mdm2, although the stability of p73a is not regulated by Mdm2.
One potentially important consequences of the interaction between p73a and Mdm2 could be in preventing Mdm2 mediated degradation of p53 through titration of Mdm2. Since p73a is not degraded by Mdm2, high levels of p73a expression could also result in the stabilization of p53. In support of this suggestion, we have seen a slight protection from Mdm2 mediated degradation following cotransfection of p73a with p53 in Saos-2 cells. As yet, signals which lead to an elevation of p73a protein have not been described. However, activation of p73a expression by any mechanism would be predicted to elicit both p73a dependent cell growth inhibition and potentially activate a p53 dependent response too. It will, therefore, be of great interest to ®nd stimuli that can induce p73a expression.
Materials and methods
Cell culture and transfection U2OS and Saos-2 osteosarcoma cell lines were maintained in DMEM supplemented with 10% fetal bovine serum. Where indicated, N-acetyl-leucinyl-leucinyl-norleucinal (LLnL, also called calpain inhibitor I, Sigma) or lactacystin (purchased from EJ Corey) was added to the media at 50 mM ®nal concentration. Cells were transfected using calcium phosphate co-precipitate, harvested after 24 h and prepared for immunoprecipitation, Western blotting or luciferase assays.
Plasmids
The plasmid expressing HA-tagged p73a (pcDNA3HA p73a) has been described (Jost et al., 1997) . The HA tag was removed and replaced by a Flag tag using PCR, creating the pCDNA3Flagp73a. Plasmids expressing the wild type human p53 (pCB6+p53Pro and pSPp53Pro (Marston et al., 1994) ), the Flag-tagged p53 (pCDNA3Flagp53 (Bates et al., 1998) ) as well as the human wild type Mdm2 (pCHDM1a) and mutant Mdm2 (pCHDMD58 ± 89 and pCHDMD222 ± 437 (Chen et al., 1995) ), mouse wild type and mutant Mdm2 (pCOCmdm2 X2 and pCOCmdm2DXM (Haupt et al., 1997) ), and HPV16 E6 (pSP65 16E6 (Marston et al., 1994) ) have been described before. The green¯uorescent protein expression plasmid (pEGFP-N1) was purchased from Clontech. The p53 responsive bax promoter luciferase construct Bax-Luc was derived from the plasmid Bax-CAT (Miyashita and Reed, 1995) .
Protein analysis and luciferase assays
Coupled transcription/translation was carried out with TNT rabbit reticulocyte lysate systems (Promega). Immunoprecipitation, Western blotting and E6-mediated degradation assay was performed as previously described (Marston et al., 1994) . Ab-1 (Calbiochem) or SMP14 (PharMingen) antibody was used to precipitate Mdm2-complexes as indicated in the Figure legends. p53 was detected with DO-1. p73a was detected with anity puri®ed rabbit polyclonal antibody that was raised against the C-terminal 18 amino acids of human p73a (CKARKQPIKEEFTEAEIH). Specificity of the antibody was con®rmed by peptide blocking. M2 and M5 anti-Flag antibodies were purchased from Sigma, while anti-GFP was purchased from Clontech. Luciferase assays were carried out as previously described (Ludwig et al., 1996) .
